Global Breast Cancer Monoclonal Antibodies Market Outlook 2020
DUBLIN, May 26, 2015 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/8nqqdw/global_breast) has announced the addition of the "Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" report to their offering.
Globally, Roche seems to dominate the breast cancer monoclonal antibody segment because of largest inventory. Its block buster molecule, Herceptin has been able to dominate this segment for several years. It was found that breast cancer cells become recalcitrant and relapsed condition could not be treated with Herceptin. This finding propelled the development of other monoclonal antibodies to overcome these shortcomings. They have been formulated using variants of Her 2 that has been found to be associates with around quarter of breast cancer cases.
They are also used in various combinations due to which they have been able to increase the survival rates and progression free disease survival. On the other hand, introduction of different products by same company for same cancer indication has created competition within the products. As a result, few products generate more sales as compared to other like Herceptin while products like Perjeta which are used in second line treatment generate modes sales.
India, Europe and Australia have been proposed as major market where biosimilar breast cancer monoclonal antibodies would be marketed in incipient stages. These market have different characteristic features due to which they are expected to witness different sales of biosimilar breast cancer monoclonal antibodies. Europe is likely to become an important market due to stringent healthcare budget and maintenance of sustainable healthcare system. European Medicine Agency (EMA) have already granted marketing approval to many biosimilar products. This shows that biosimilar breast cancer monoclonal antibodies are likely to generate significant revenues in European market. Indian market may face slightly slow market growth due to patent issues.
However, such issues are expected to be resolved in coming years leading to higher sales. Large population size and escalating breast cancer incidences along with affordable pricing are expected to generate more sales of biosimilar breast cancer monoclonal antibodies. Australia has also shown positive response for these drugs and they are like to import it from countries like India where high production could be achieved at competitive pricing. US market is also likely to open in coming years due to which this category would observe significant growth. In this way, the future of breast cancer monoclonal antibodies seems to be optimistic.
"Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
- Breast Cancer Monoclonal Antibodies Mechanism
- Global Breast Cancer Monoclonal Antibody Market Analysis
- Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
- Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
- Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
- Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
- Bevacizumab (Avastin®)
- Pertuzumab (Omnitarg, Perjeta®)
- Trastuzumab (Herceptin®)
- Trastuzumab Biosimilar (Hertraz & CANMAb)
- Trastuzumab Emtansine (Kadcyla®)
- Trastuzumab Subcutaneous (Herceptin®)
Key Topics Covered:
1. Introduction to Monoclonal Antibodies
2. Need for Monoclonal Antibodies for Cancer Treatment
3. Breast Cancer Monoclonal Antibodies Mechanism
4. Global Breast Cancer Monoclonal Antibody Market Analysis
5. Global Breast Cancer Monoclonal Antibody Market Dynamics
6. Global Breast Cancer Monoclonal Antibodies Market Future Prospects
7. Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
8. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
9. Discontinued & Suspended Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
10. Competitive Landscape
- Amgen
- Biocad
- Biocon
- Celltrion Pharm
- CuraGen Corporation
- Dyax Corp
- GlaxoSmithKline
- ImmunoGen
- MacroGenics
- Merck
- Merrimack Pharmaceuticals
- Novartis
- Pfizer
- Pierre Fabre
- Recombio
- Roche Holding
- Samsung Bioepis
- Synthon
For more information visit http://www.researchandmarkets.com/research/8nqqdw/global_breast
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article